One Year Outcomes from VENOS-1 First-in-Human Study of the Velocity® pAVF System Published in the Journal of Endovascular Therapy

Dec 1, 2025

Los Gatos, California – December 1, 2025 – Venova Medical, a privately held company developing a next generation technology for the creation of percutaneous arteriovenous fistulas (pAVF) for hemodialysis access, announced today the publication of first-in-human...

Mid-Term Outcomes from VENOS-2 Early Feasibility Study of the Velocity® pAVF System Reported during 2025 Controversies in Dialysis Access (CiDA) Meeting

Nov 3, 2025

Rishi Razdan, MD, Medical Director of Azura Vascular Care Jacksonville in Jacksonville, Florida, presented mid-term results from the Venova Medical sponsored VENOS-2 study during the 2025 Controversies in Dialysis Access (CiDA) meeting held in Boston, Massachusetts....

Venova Medical to Present Results from VENOS-1 Study at American Society of Nephrology (ASN) Kidney Week 2024

Oct 15, 2024

(Los Gatos, California) – Venova Medical, Inc. (Venova Medical), a privately held company developing a next generation technology for the creation of percutaneous arteriovenous fistulas (pAVF) for hemodialysis access today announced that it will present an oral...

Renal Interventions Reports on Dr. Robert Shahverdyan’s Presentation of Results from VENOS-1 Study during the 2024 Controversies in Dialysis Access (CiDA) meeting

Oct 15, 2024

Robert Shahverdyan, MD, from Hamburg, Germany presented one-year results from the VENOS-1 first-in-human study, which examined the VelocityTM Percutaneous Arteriovenous Fistula (pAVF) System during the recent Controversies in Dialysis Access (CiDA) meeting held in...

Secondary interventions to assist pAVF maturation remain commonplace for current endoAVF devices

Jul 3, 2023

While currently available percutaneous arteriovenous fistula (pAVF) devices have demonstrated a high rate of technical procedural success, secondary interventions are often required to achieve fistula maturation with these devices. CLICK HERE to read an excellent...

Robert Shahverdyan, MD presents insights from initial clinical experience with the Velocity System during Charing Cross (CX) Symposium

May 8, 2023

During the recent Charing Cross (CX) International Symposium held in London, Robert Shahverdyan, MD detailed the challenges associated with the use of current endovascular arteriovenous fistula (endoAVF) devices and provided insights from his clinical experience with...